Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s share price reached a new 52-week high on Wednesday . The company traded as high as $31.56 and last traded at $32.2630, with a volume of 1213266 shares. The stock had previously closed at $26.29.
Immunovant News Summary
Here are the key news stories impacting Immunovant this week:
- Positive Sentiment: Immunovant reported strong Phase 2 rheumatoid arthritis data for IMVT-1402, with ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8%, respectively, fueling optimism about the drug’s efficacy. Article Title
- Positive Sentiment: Roivant-backed coverage highlighted the results as a validation of the broader investment case, suggesting the clinical win could support value creation across Immunovant’s autoimmune pipeline. Article Title
- Positive Sentiment: Management also said the cutaneous lupus proof-of-concept trial is fully enrolled, with topline data expected in the second half of 2026, giving investors another potential catalyst. Article Title
- Positive Sentiment: The company reported a strong cash position of about $902 million as of March 31, which should help fund development and extend runway toward a possible future launch. Article Title
- Neutral Sentiment: The quarterly loss was wider than expected, with EPS of -$0.73 versus estimates for -$0.60, but investors appear to be focusing more on the clinical readout than the earnings miss. Article Title
- Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged Rule 10b5-1 transaction, which may slightly weigh on sentiment even though the sale was planned in advance. Article Title
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on IMVT shares. Guggenheim boosted their target price on shares of Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a report on Wednesday, April 8th. Sanford C. Bernstein started coverage on shares of Immunovant in a report on Friday, March 20th. They issued a “market perform” rating and a $28.00 target price on the stock. Citigroup restated a “buy” rating on shares of Immunovant in a report on Thursday. Finally, HC Wainwright boosted their target price on shares of Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $34.44.
Immunovant Stock Performance
The company has a market capitalization of $6.95 billion, a P/E ratio of -12.28 and a beta of 0.70. The firm’s fifty day moving average is $26.65 and its 200 day moving average is $25.85.
Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter in the prior year, the company posted ($0.64) EPS. On average, analysts forecast that Immunovant, Inc. will post -2.6 EPS for the current year.
Insiders Place Their Bets
In other Immunovant news, Director Atul Pande sold 6,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $32.00, for a total value of $192,000.00. Following the transaction, the director directly owned 116,731 shares in the company, valued at $3,735,392. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 14,229 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $24.10, for a total transaction of $342,918.90. Following the completion of the transaction, the chief executive officer owned 19,561 shares in the company, valued at $471,420.10. This represents a 42.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 78,141 shares of company stock worth $2,115,713. 1.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On Immunovant
A number of hedge funds have recently added to or reduced their stakes in IMVT. RTW Investments LP bought a new position in Immunovant in the 4th quarter worth about $80,781,000. Morgan Stanley lifted its position in shares of Immunovant by 147.4% in the 4th quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock worth $123,195,000 after purchasing an additional 2,887,359 shares during the period. Jennison Associates LLC lifted its position in shares of Immunovant by 356.4% in the 1st quarter. Jennison Associates LLC now owns 3,196,705 shares of the company’s stock worth $79,406,000 after purchasing an additional 2,496,241 shares during the period. ADAR1 Capital Management LLC lifted its position in shares of Immunovant by 319.0% in the 3rd quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock worth $36,137,000 after purchasing an additional 1,706,687 shares during the period. Finally, Logos Global Management LP lifted its position in shares of Immunovant by 400.0% in the 4th quarter. Logos Global Management LP now owns 1,375,000 shares of the company’s stock worth $34,952,000 after purchasing an additional 1,100,000 shares during the period. 47.08% of the stock is currently owned by institutional investors.
Immunovant Company Profile
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
Featured Stories
- Five stocks we like better than Immunovant
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
